Sanofi (SNY) Tops Q1 EPS by 85c; reaffirms guidance

Sanofi (NASDAQ: SNY) reported Q1 EPS of EUR1.78, EUR0.85 better than the analyst estimate of EUR0.93. Revenue for the quarter came in at EUR10.46 billion versus the consensus estimate of EUR11.47 billion.

GUIDANCE

Sanofi expects 2024 business EPS to remain roughly stable excluding the impact of an expected effective tax rate increase to 21% and decrease low single-digit at CER including the higher expected tax rate, barring unforeseen major adverse events. Applying average April 2024 exchange rates, the currency impact on 2024 business EPS is estimated between -5.5% to -6.5%.

For earnings history and earnings-related data on Sanofi (SNY) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight